tirzepatide vs brenipatide

tirzepatide (S-tier) vs brenipatide (C-tier). mechanism, trials, evidence boundaries, dosing literature. side-by-side reference.

tirzepatide · tier S

A dual GIP and GLP-1 receptor agonist with distinct Zepbound and Mounjaro labels.

The obesity record is strong, but every outcome must stay attached to its trial population and product label.

20.9% SURMOUNT-1 mean change at 15 mg · half-life ~5 days · weight loss

brenipatide · tier C

Brenipatide, Lilly code LY3537031, is a modified 39 amino acid peptide that activates both GIP and GLP-1 receptors. The registry has 11 records indexed under Brenipatide and 5 earlier LY3537031-only registrations. None of the 16 has posted results.

Brenipatide is an investigational subcutaneous dual GIP and GLP-1 receptor agonist being studied in people. The registered program is large, but effect and safety remain unknown because no record has posted results.

16 records all without posted results · weight loss

at a glance

• tirzepatide: tier S · 20.9% SURMOUNT-1 mean change at 15 mg
• brenipatide: tier C · 16 records all without posted results

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.